brand logo

Am Fam Physician. 2022;105(6):570

Original Article: Topical Corticosteroids: Choice and Application
Issue Date: March 15, 2021

To the Editor: The article by Drs. Stacey and McEleney references the traditional use of vasoconstriction assays to determine potency. These assays were originally described in 1962 and have evolved only minimally since then.1 It was hypothesized that the degree of skin blanching correlated with the degree of cutaneous absorption of topical corticosteroids and clinical effectiveness. Although advances in quantification have been developed, vasoconstriction still determines the potency of topical corticosteroids.2 

However, the vasoconstriction assay lacks standardization and is limited in its ability to correlate potency to clinical effectiveness. The mechanisms of action of topical corticosteroids are hypothesized to be multifactorial, including antiproliferation, antipruritic, immunomodulation, and vasoconstriction. Vasoconstriction assays may not be the ideal measurement of potency and clinical effectiveness.35 

Data on vasoconstriction assays of the skin of people of color are extremely limited, and most studies measuring the effects of medications on the skin are predominately in White patients.1,6 Aging affects skin characteristics, including thinning of the epidermis and decreased vascularity of the dermis. Although older adults have not traditionally been included in vasoconstriction assay studies, physiologically, changes attributed to aging are likely to affect these assays and may alter the pharmacokinetics of topical corticosteroids in older adults. This variable is not accounted for in the current classification of the potency of topical steroids. 

Family physicians should recognize the significant limitations of current standards of measurements of topical corticosteroid potency because these may not reflect the variety of skin colors and ages of our patients.

In Reply: Thank you for highlighting these significant limitations of the vasoconstriction assay. Some studies support ordering the clinical potency of topical corticosteroids as determined by the vasoconstriction assay.14 Current practice is to prescribe topical corticosteroids according to potency charts, which were created using data gathered from their performance on the vasoconstriction assay. No alternative model has been widely adopted as an acceptable replacement. 

Despite its disadvantages, the vasoconstriction assay has several advantages. It assesses how effectively the corticosteroid is absorbed and how the compound activates steroid receptors.5 It is relatively inexpensive and easy to perform in a standardized setting. Data exist for each steroid preparation's performance on the vasoconstriction assay. There are relatively sparse data comparing the numerous preparations for pathologies, ages, and the skin types you describe.

Email letter submissions to afplet@aafp.org. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors. Letters submitted for publication in AFP must not be submitted to any other publication. Letters may be edited to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.